<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name>ООО «Издательство "Открытые системы"»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2024.27.6.011</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1256</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНАЯ ТЕМА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TOPICAL THEME</subject></subj-group></article-categories><title-group><article-title>Эффективность препаратов ботулинического токсина типа А при последствиях огнестрельных ранений (клинический случай)</article-title><trans-title-group xml:lang="en"><trans-title>The effectiveness of botulinum toxin type A preparations in the consequences of gunshot wounds (clinical case)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8181-3991</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дутова</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Dutova</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дутова Татьяна Ивановна, к.м.н., заведующая неврологическим отделением для больных с нарушением мозгового кровообращения</p><p>394065, Воронеж, просп. Патриотов, 23</p></bio><bio xml:lang="en"><p>Tatyana I. Dutova, Cand. of Sci. (Med.), Head of the neurological department for patients with cerebral circulation disorders</p><p>23 Patriotov ave., Voronezh, Russia, 394065</p></bio><email xlink:type="simple">Dutova80@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2359-9215</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Банин</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Banin</surname><given-names>I. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Банин Игорь Николаевич, к.м.н., министр </p><p>394006, Воронеж, ул. Красноармейская, 52д</p></bio><bio xml:lang="en"><p>Igor N. Banin, Cand. of Sci. (Med.), Minister of Health of the Voronezh region</p><p>52d Krasnoarmeyskaya str., Voronezh, 394006</p></bio><email xlink:type="simple">banin_igor@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-6920-4324</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лютиков</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyutikov</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лютиков Юрий Владимирович, к.м.н., главный врач</p><p>394065, Воронеж, просп. Патриотов, 23</p></bio><bio xml:lang="en"><p>Yuri V. Lyutikov, Cand. of Sci. (Med.), Head Doctor</p><p>23 Patriotov ave., Voronezh, Russia, 394065</p></bio><email xlink:type="simple">lyutikovyv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7197-6009</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ермоленко</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ermolenko</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ермоленко Наталия Александровна, д.м.н., член правления Российской противоэпилептической лиги, федеральный эксперт по специальности «Неврология», федеральный эксперт в области диагностики и лечения эпилепсии, вице-президент Объединения врачей-эпилептологов и пациентов Российского подразделение International Bureau for Epilepsy, заведующая кафедрой неврологии</p><p>394622, Воронеж, ул. Студенческая, 10</p></bio><bio xml:lang="en"><p>Nataliya A. Ermolenko, Dr. of Sci. (Med.), Member of the Board of the Russian Antiepileptic League, federal expert in the specialty "Neurology", federal expert in the field of diagnosis and treatment of epilepsy, Vice President of the Association of Epileptologists and Patients (Russian division of the International Bureau for Epilepsy), Head of the Department of Neurology</p><p>10 Studentskaya str., Voronezh, 394622</p></bio><email xlink:type="simple">ermola@bk.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3114-3541</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юров</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yurov</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юров Павел Валентинович, заведующий нейрохирургическим отделением </p><p>394065, Воронеж, просп. Патриотов, 23</p></bio><bio xml:lang="en"><p>Pavel V. Yurov, Head of the Neurosurgical Department</p><p>23 Patriotov ave., Voronezh, Russia, 394065</p></bio><email xlink:type="simple">yurov78@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-7744-3850</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Портных</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Portnykh</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Портных Елена Александровна, медицинская сестра нейрохирургического отделения</p><p>394065, Воронеж, просп. Патриотов, 23</p></bio><bio xml:lang="en"><p>Elena A. Portnykh, a nurse of the Neurosurgical Department</p><p>23 Patriotov ave., Voronezh, Russia, 394065</p></bio><email xlink:type="simple">elena3u9496@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Воронежская городская клиническая больница скорой медицинской помощи № 1</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voronezh City Clinical Hospital of Emergency Medical Care No. 1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Министерство здравоохранения Воронежской области</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ministry of Health of the Voronezh Region</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Воронежский государственный медицинский университет имени Н. Н. Бурденко</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voronezh State Medical University named after N. N. Burdenko</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>11</day><month>06</month><year>2024</year></pub-date><volume>0</volume><issue>6</issue><fpage>78</fpage><lpage>83</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Дутова Т.И., Банин И.Н., Лютиков Ю.В., Ермоленко Н.А., Юров П.В., Портных Е.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Дутова Т.И., Банин И.Н., Лютиков Ю.В., Ермоленко Н.А., Юров П.В., Портных Е.А.</copyright-holder><copyright-holder xml:lang="en">Dutova T.I., Banin I.N., Lyutikov Y.V., Ermolenko N.A., Yurov P.V., Portnykh E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1256">https://journal.lvrach.ru/jour/article/view/1256</self-uri><abstract><sec><title>Введение</title><p>Введение. Реалии последних двух лет специальной военной операции сподвигли врачей всех специальностей по-новому оценить особенности выбора методов диагностики, лечения, обезболивания пациентов с последствиями огнестрельных ранений. В статье представлен клинический случай лечения с помощью ботулинотерапии выраженного болевого синдрома, синдрома грушевидной мышцы вследствие огнестрельного ранения. Ботулотоксин А обладает уникальным обезболивающим действием, что расширило сферу его применения в клинической практике.</p></sec><sec><title>Цель работы</title><p>Цель работы. Оценить эффективность препаратов ботулинического токсина типа А при выраженном болевом синдроме вследствие огнестрельных ранений.</p></sec><sec><title>Результаты</title><p>Результаты. В результате лечения ботулотоксином А получена выраженная положительная динамика купирования болевого синдрома при синдроме грушевидной мышцы, развившемся в результате огнестрельного ранения.</p></sec><sec><title>Заключение</title><p>Заключение. Синдром грушевидной мышцы часто маскируется под клиническую картину различных патологий. Несвоевременно поставленный диагноз или неадекватная терапия могут привести к патологическим изменениям седалищного нерва. Залог эффективности применяемой методики — раннее выявление данного заболевания. В настоящее время спектр лекарственных средств для лечения болевого синдрома очень широк, но только методологически правильно проведенная инъекция позволяет повысить эффективность лечения синдрома грушевидной мышцы и уменьшить риск осложнений, что невозможно без применения методов визуализации. Таким образом, мы считаем, что инъекции в область грушевидной мышцы под контролем визуализации должны стать методом выбора при терапии боли данной локализации. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. The events of the last two years of a Special Military Operation have obliged doctors of all specialties to re-evaluate the methods of diagnosis, treatment, and anesthesia of patients with the consequences of gunshot wounds. The article presents a clinical case of a severe pain syndrome (piriform muscle syndrome) due to a gunshot wound and its treatment using botulinum therapy. Botulinum toxin type A has a unique analgesic effect, which has expanded the scope of its application in clinical practice.</p></sec><sec><title>Objective</title><p>Objective. The purpose of the study was to evaluate the effectiveness of botulinum toxin type A preparations in severe pain syndrome due to gunshot wounds.</p></sec><sec><title>Results</title><p>Results. As a result of the treatment with botulinum toxin type A, a pronounced positive dynamics of pain relief was obtained in case of piriform muscle syndrome, which developed as a result of the consequences of a gunshot wound.</p></sec><sec><title>Conclusion</title><p>Conclusion. Piriform muscle syndrome is a disorder that often manifests as a clinical picture of different pathologies. A late diagnosis or inadequate therapy can lead to the pathological changes in the sciatic nerve. The key to the effectiveness of the method used is the early detection of such disorder. Currently, the range of preparations for the treatment of pain syndrome is quite wide, but only a methodologically proper injection can increase the effectiveness of piriform muscle syndrome treatment and reduce the risk of complications, which is impossible without the use of imaging techniques. Thus, we believe that injections into the area of the piriform muscle under the visualization control should become the method of choice in the treatment of pain of such localization.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ботулотоксин А</kwd><kwd>ботулинотерапия</kwd><kwd>огнестрельное ранение</kwd><kwd>специальная военная операция</kwd><kwd>синдром грушевидной мышцы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>botulinum antitoxin type A</kwd><kwd>botulinum therapy</kwd><kwd>gunshot wound</kwd><kwd>special military operation</kwd><kwd>piriform muscle syndrome</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Aoki K. R. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neuro Toxicology. 2005; 26: 785-793.</mixed-citation><mixed-citation xml:lang="en">Aoki K. R. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neuro Toxicology. 2005; 26: 785-793.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Goadsby P. J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48-56.</mixed-citation><mixed-citation xml:lang="en">Goadsby P. J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48-56.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gobel H., Heinze A., Heinze-Kuhn K., Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001; 91: 195-199.</mixed-citation><mixed-citation xml:lang="en">Gobel H., Heinze A., Heinze-Kuhn K., Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001; 91: 195-199.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wheeler A. H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache. 1998; 38 (6): 468-471.</mixed-citation><mixed-citation xml:lang="en">Wheeler A. H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache. 1998; 38 (6): 468-471.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Silberstein S. D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001; 2 (10): 1649-1654.</mixed-citation><mixed-citation xml:lang="en">Silberstein S. D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001; 2 (10): 1649-1654.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Aoki K. R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003; 43 (Suppl 1): 9-15.</mixed-citation><mixed-citation xml:lang="en">Aoki K. R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003; 43 (Suppl 1): 9-15.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dressler D., Saberi F. A., Barbosa E. R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005; 63: 180-185.</mixed-citation><mixed-citation xml:lang="en">Dressler D., Saberi F. A., Barbosa E. R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005; 63: 180-185.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Durham P. L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011; 51 (10): 1573-1577.</mixed-citation><mixed-citation xml:lang="en">Durham P. L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011; 51 (10): 1573-1577.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gazerani P., Staahl C., Drewes A. M., Arendt-Nielsen L. The effects of Botulinum Toxin type A on cap-saicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006; 122 (3): 315-325.</mixed-citation><mixed-citation xml:lang="en">Gazerani P., Staahl C., Drewes A. M., Arendt-Nielsen L. The effects of Botulinum Toxin type A on cap-saicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006; 122 (3): 315-325.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gazerani P., Pedersen N. S., Staahl C., et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009; 141 (1-2): 60-69.</mixed-citation><mixed-citation xml:lang="en">Gazerani P., Pedersen N. S., Staahl C., et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009; 141 (1-2): 60-69.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000; 59 (11): 1403-1406.</mixed-citation><mixed-citation xml:lang="en">Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000; 59 (11): 1403-1406.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Welch M. J., Purkiss J. R., Foster K. A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38 (2): 245-258.</mixed-citation><mixed-citation xml:lang="en">Welch M. J., Purkiss J. R., Foster K. A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38 (2): 245-258.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Aoki K. R. Evidence for antinociceptive activity of botulinumtoxin type A in pain management. Headache. 2003; 43 (Suppl 1): 9-15.</mixed-citation><mixed-citation xml:lang="en">Aoki K. R. Evidence for antinociceptive activity of botulinumtoxin type A in pain management. Headache. 2003; 43 (Suppl 1): 9-15.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Aoki K. R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005; 26 (5): 785-793.</mixed-citation><mixed-citation xml:lang="en">Aoki K. R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005; 26 (5): 785-793.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gazerani P., Pedersen N. S., Staahl C., et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009; 141 (1-2): 60-69.</mixed-citation><mixed-citation xml:lang="en">Gazerani P., Pedersen N. S., Staahl C., et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009; 141 (1-2): 60-69.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Артеменко А. Р., Орлова О. Р. Ботулинический токсин типа А: расширение возможностей терапии первичных головных болей. Врач. 2007; 5: 40-43.</mixed-citation><mixed-citation xml:lang="en">Артеменко А. Р., Орлова О. Р. Ботулинический токсин типа А: расширение возможностей терапии первичных головных болей. Врач. 2007; 5: 40-43.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Santamato A., Micello M. F., Valeno G., Beatrice R., Cinone N., Baricich A., Picelli A., Panza F., Logroscino G., Fiore P., Ranieri M. Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins (Basel). 2015; 7 (8): 3045-3056. https://doi.org/10.3390/toxins7083045.</mixed-citation><mixed-citation xml:lang="en">Santamato A., Micello M. F., Valeno G., Beatrice R., Cinone N., Baricich A., Picelli A., Panza F., Logroscino G., Fiore P., Ranieri M. Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins (Basel). 2015; 7 (8): 3045-3056. https://doi.org/10.3390/toxins7083045.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Al-Shaikh M., Michel F., Parratte B., Kastler B., Vidal C., Aubry S. An MRI evaluation of changes in piriformis muscle morphology induced by botulinum toxin injections in the treatment of piriformis syndrome. Diagn. Interv. Imaging. 2015; 96 (1): 37-43. https://doi.org/10.1016/j.diii.2014.02.015.</mixed-citation><mixed-citation xml:lang="en">Al-Al-Shaikh M., Michel F., Parratte B., Kastler B., Vidal C., Aubry S. An MRI evaluation of changes in piriformis muscle morphology induced by botulinum toxin injections in the treatment of piriformis syndrome. Diagn. Interv. Imaging. 2015; 96 (1): 37-43. https://doi.org/10.1016/j.diii.2014.02.015.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez-Pinero M., Vidal Vargas V., Jimenez Sarmiento A. S. Long-Term Effi cacy of Ultrasound-Guided Injection of IncobotulinumtoxinA in Piriformis Syndrome. Pain Med. 2018; 19 (2): 408-411. https://doi.org/10.1093/pm/pnx135</mixed-citation><mixed-citation xml:lang="en">Rodriguez-Pinero M., Vidal Vargas V., Jimenez Sarmiento A. S. Long-Term Effi cacy of Ultrasound-Guided Injection of IncobotulinumtoxinA in Piriformis Syndrome. Pain Med. 2018; 19 (2): 408-411. https://doi.org/10.1093/pm/pnx135</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ripellino P., Cianfoni A., Izzo M. G. A., Gobbi C. Relapsing piriformis syndrome treated with botulinum toxin injections. Brit.med. J. Case Rep. 2019; 12: e230981. https://doi.org/10.1136/bcr-2019-230981.</mixed-citation><mixed-citation xml:lang="en">Ripellino P., Cianfoni A., Izzo M. G. A., Gobbi C. Relapsing piriformis syndrome treated with botulinum toxin injections. Brit.med. J. Case Rep. 2019; 12: e230981. https://doi.org/10.1136/bcr-2019-230981.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Fishman L. M., Wilkins A. N., Rosner B. Electrophysiologically identifi ed piriformis syndrome is successfully treated with incobotulinum toxin a and physical therapy. Muscle Nerve. 2017; 56 (2): 258-263. https://doi.org/10.1002/mus.25504.</mixed-citation><mixed-citation xml:lang="en">Fishman L. M., Wilkins A. N., Rosner B. Electrophysiologically identifi ed piriformis syndrome is successfully treated with incobotulinum toxin a and physical therapy. Muscle Nerve. 2017; 56 (2): 258-263. https://doi.org/10.1002/mus.25504.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Santamato A., Micello M. F., Valeno G., Beatrice R., Cinone N., Baricich A., Picelli A., Panza F., Logroscino G., Fiore P., Ranieri M. Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins (Basel). 2015; 7 (8): 3045-3056. https://doi.org/10.3390/toxins7083045.</mixed-citation><mixed-citation xml:lang="en">Santamato A., Micello M. F., Valeno G., Beatrice R., Cinone N., Baricich A., Picelli A., Panza F., Logroscino G., Fiore P., Ranieri M. Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins (Basel). 2015; 7 (8): 3045-3056. https://doi.org/10.3390/toxins7083045.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Fabregat G., Rosello M., Asensio-Samper J. M., Villaneuva-Perez V. L., Martinez-Sanjuan V., De Andres J., Eichenberger U. Computertomographic verifi cation of ultrasound-guided piriformis muscle injection: a feasibility study. Pain Physic. 2014; 17 (6): 507-513.</mixed-citation><mixed-citation xml:lang="en">Fabregat G., Rosello M., Asensio-Samper J. M., Villaneuva-Perez V. L., Martinez-Sanjuan V., De Andres J., Eichenberger U. Computertomographic verifi cation of ultrasound-guided piriformis muscle injection: a feasibility study. Pain Physic. 2014; 17 (6): 507-513.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Koh E., Webster D., Boyle J. Case report and review of the potential role of the Type A piriformis muscle in dynamic sciatic nerve entrapment variant of piriformis syndrome. Surg. Radiol. Anat. 2020; 42 (10): 1237-1242. https://doi.org/10.1007/s00276-020-02440-8.</mixed-citation><mixed-citation xml:lang="en">Koh E., Webster D., Boyle J. Case report and review of the potential role of the Type A piriformis muscle in dynamic sciatic nerve entrapment variant of piriformis syndrome. Surg. Radiol. Anat. 2020; 42 (10): 1237-1242. https://doi.org/10.1007/s00276-020-02440-8.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fritz J., Chhabra A., Wang K. C., Carrino J. A. Magnetic resonance neurography-guided nerve blocks for the diagnosis and treatment of chronic pelvic pain syndrome. Neuroimag. Clin. N. Amer. 2014; 24 (1): 211-234. https://doi.org/10.1016/j.nic.2013.03.028.</mixed-citation><mixed-citation xml:lang="en">Fritz J., Chhabra A., Wang K. C., Carrino J. A. Magnetic resonance neurography-guided nerve blocks for the diagnosis and treatment of chronic pelvic pain syndrome. Neuroimag. Clin. N. Amer. 2014; 24 (1): 211-234. https://doi.org/10.1016/j.nic.2013.03.028.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Fishman L. M., Wilkins A. N., Rosner B. Electrophysiologically identifi ed piriformis syndrome is successfully treated with incobotulinum toxin a and physical therapy. Muscle Nerve. 2017; 56 (2): 258-263. https://doi.org/10.1002/mus.25504.</mixed-citation><mixed-citation xml:lang="en">Fishman L. M., Wilkins A. N., Rosner B. Electrophysiologically identifi ed piriformis syndrome is successfully treated with incobotulinum toxin a and physical therapy. Muscle Nerve. 2017; 56 (2): 258-263. https://doi.org/10.1002/mus.25504.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
